• Aurinia Pharmaceuticals reported strong commercial performance in LUPKYNIS, contributing to higher net income supported by a tax benefit.
• The company initiated a new clinical study of aritinercept for autoimmune diseases, expanding its development pipeline.
• A pediatric VOCAL study was terminated, and Aurinia is now working with regulators to address pediatric requirements.

Aurinia Pharmaceuticals, listed as NasdaqGM:AUPH, is drawing attention after stronger LUPKYNIS sales and a tax benefit helped lift net income. The shares last closed at $14.17, with a 1 year return of 78.2% and a 3 year return of 57.6%, while the 5 year return stands at 8.3%. Recent shorter term moves include a 1.6% decline over the past week and a 2.5% decline over the past month, alongside a 7.7% decline year to date.

For investors, the combination of commercial traction in LUPKYNIS and active work on new autoimmune treatments such as aritinercept helps clarify where management is focusing resources. The setback in the pediatric VOCAL study and ongoing talks with regulators are important to watch, as they will influence how Aurinia addresses pediatric needs within its overall development plan.

Stay updated on the most important news stories for Aurinia Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Aurinia Pharmaceuticals.

Quick Assessment

• ✅ Price vs Analyst Target: At $14.17, the share price sits about 17% below the US$17.00 analyst target, with estimates ranging from US$15.00 to US$21.00.
• ✅ Simply Wall St Valuation: The stock is flagged as undervalued, trading around 63.6% below the internal fair value estimate.
• ❌ Recent Momentum: The 30 day return of roughly 2.5% decline shows recent weakness despite improved net income.

There is only one way to determine whether it is the right time to buy, sell or hold Aurinia Pharmaceuticals. Head to Simply Wall St's company report for the latest analysis of Aurinia Pharmaceuticals's fair value.

Key Considerations

• 📊 Strong LUPKYNIS sales and a tax driven boost to net income clarify how much earnings currently rely on this product and one off support.
• 📊 It may be useful to monitor aritinercept trial progress, revenue trends and whether the current P/E of 6.56 moves closer to the Biotechs industry average of 21.75.
• ⚠️ The company has two major flagged risks, including a high level of non cash earnings, which can make headline profit quality harder to assess.

Dig Deeper

For a more complete view, including additional risks and potential opportunities, visit the complete Aurinia Pharmaceuticals analysis. You can also explore the community page for Aurinia Pharmaceuticals to see how other investors believe this latest news will affect the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.